Dose Insider / Glossary / Saxenda

SaxendaWhat it is, who it is for and how it compares

Updated November 20, 2026 路 3 min read 路 SAXENDA prescribing information, DailyMed, June 2026

Saxenda is a brand of liraglutide, a once-daily injection made by Novo Nordisk for weight management. Used with a reduced-calorie diet and more physical activity, it is approved to lower body weight and keep it off. The label covers adults with obesity, adults with overweight and at least one weight-related condition, and children aged 12 and older with obesity who weigh more than 60 kg.

7.4%Without diabetes, Saxenda 3 mg, weight lost by week 56
Weight lost by week 56Saxenda label trials, % of starting weightWITHOUT DIABETESSaxenda 3 mg7.4%Placebo3.0%WITH TYPE 2 DIABETESSaxenda 3 mg5.4%Placebo1.7%Weight lost by week 56Saxenda label trials, % of starting weightWITHOUT DIABETESSaxenda 3 mg7.4%Placebo3.0%WITH TYPE 2 DIABETESSaxenda 3 mg5.4%Placebo1.7%

62.3% without diabetes lost at least 5% of their weight, against 34.4% on placebo.

On this page

It is the same molecule as Victoza, which is approved for type 2 diabetes at lower doses.1,2

What it is

Liraglutide is a GLP-1 receptor agonist, an older relative of semaglutide from the same maker. The label explains why a modified molecule is needed: the body's own GLP-1 has a half-life of only 1.5 to 2 minutes because enzymes break it down. Liraglutide is 97% similar to human GLP-1, carries a 16-carbon fatty acid on a spacer, and resists those enzymes, which stretches its half-life to about 13 hours.1 That is long enough for one shot a day, but not one a week as with semaglutide.

How the dose climbs

Saxenda is injected once a day under the skin. The dose rises every week: 0.6 mg in week 1, then 1.2 mg, 1.8 mg, 2.4 mg and, from week 5, 3 mg. For adults 3 mg is the only treatment dose; the lower ones are for the climb. If 3 mg cannot be tolerated, the label says to stop Saxenda, and if a step causes trouble the climb can be delayed by about a week.1

The label also sets a test that the newer weekly medicines do not have. Sixteen weeks after starting, weight is checked, and if an adult has not lost at least 4% of starting weight, Saxenda is to be stopped, since clinically meaningful weight loss is then unlikely with more treatment.1

What it did in trials

Three 56-week trials support the weight approval in adults.1

The weekly medicines that followed lower weight further in their own trials: 14.9% on Wegovy 2.4 mg over 68 weeks, for example.3 The trials were run separately and are not a direct comparison. Our Wegovy weight loss chart shows how the Wegovy curve builds week by week.

Side effects and warnings

In the label's trials, nausea was reported by 39.3% on Saxenda against 13.8% on placebo, diarrhea by 20.9% against 9.9%, constipation by 19.4% against 8.5% and vomiting by 15.7% against 3.9%. Injection-site reactions were reported by 13.9% against 10.5%.1 Our page on nausea on a GLP-1 covers what helps.

Saxenda carries the boxed warning about thyroid C-cell tumors seen in rats and mice and must not be used by people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. It is not to be combined with another liraglutide product or with any other GLP-1 receptor agonist. Its label dropped the warning on suicidal behavior and ideation in February 2026.1

Saxenda in eight lines

FactSaxenda
Active ingredientLiraglutide
MakerNovo Nordisk
First U.S. approval2010, as liraglutide
How oftenOnce a day, under the skin
Treatment dose3 mg, reached in week 5
Half-lifeAbout 13 hours
Stop ruleUnder 4% lost by week 16
Youngest age12, over 60 kg

SAXENDA prescribing information, DailyMed version of June 15, 2026.1

Victoza is liraglutide for type 2 diabetes at up to 1.8 mg a day. Wegovy and Zepbound are the weekly injections approved for the same weight use. Our page on GLP-1 costs without insurance compares self-pay prices.

Sources

  1. SAXENDA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, U.S. National Library of Medicine, version published June 15, 2026; boxed warning, recent major changes and sections 1, 2, 6.1, 11, 12 and 14. dailymed.nlm.nih.gov
  2. VICTOZA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, U.S. National Library of Medicine, version published November 17, 2025; section 1. dailymed.nlm.nih.gov
  3. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; section 14. accessdata.fda.gov

Related analyses

Log each daily Saxenda dose and your weight, and see week 16 coming.

Open Dose Insider